There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cassava Sciences (SAVA – Research Report) and CymaBay Therapeutics (CBAY – Research Report) with bullish sentiments.
Cassava Sciences (SAVA)
H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Cassava Sciences today and set a price target of $124.00. The company’s shares closed last Tuesday at $22.30.
According to TipRanks.com, Bernardino is a 4-star analyst with an average return of
Cassava Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $99.50, implying a 360.0% upside from current levels. In a report released yesterday, JonesTrading also maintained a Buy rating on the stock with a $75.00 price target.
See today’s best-performing stocks on TipRanks >>
CymaBay Therapeutics (CBAY)
In a report released today, Patrick Dolezal from LifeSci Capital reiterated a Buy rating on CymaBay Therapeutics, with a price target of $21.00. The company’s shares closed last Tuesday at $16.44, close to its 52-week high of $18.20.
According to TipRanks.com, Dolezal is a 3-star analyst with an average return of
CymaBay Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $24.30, which is a 48.5% upside from current levels. In a report issued on October 25, JonesTrading also maintained a Buy rating on the stock with a $19.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SAVA:
- Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results
- Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease
- Cassava Sciences completes patient enrollment for Phase 3 program of simufilam
- Cassava Sciences put volume heavy and directionally bearish
- Largest borrow rate increases among liquid names
